on Fresenius SE & Co. KGaA (ETR:FRE)
Fresenius Appoints Mahl to Management Board and Extends Hennicken’s Contract
The Supervisory Board of Fresenius SE & Co. KGaA has appointed Dr. Marc-Alexander Mahl to the Management Board, effective November 1, 2026. Mahl will oversee the Fresenius Kabi businesses, succeeding Pierluigi Antonelli. Alongside this, Sara Hennicken’s role as Chief Financial Officer (CFO) has been extended for an additional five years, securing her position until 2032.
Marc-Alexander Mahl, a seasoned executive with over 20 years at Fresenius, will continue to lead the Pharma Business Unit amidst growing strategic importance. His expanded role includes supervision over the Nutrition business, now directed by Sébastien Guery. Guery, having held various management positions at international companies, will report directly to Mahl.
These leadership changes align with Fresenius's #FutureFresenius initiative, emphasizing sustainable and profitable growth. The company is positioning its leadership team for future challenges and opportunities, focusing on innovation-driven growth within the Biopharma, MedTech, and Nutrition sectors.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Fresenius SE & Co. KGaA news